Sector Update: Health Care Stocks Decline in Late Afternoon Trading

MT Newswires Live06-29

Health care stocks were retreating late Friday afternoon, with the NYSE Health Care Index down 0.3% and the Health Care Select Sector SPDR Fund (XLV) shedding 0.4%.

The iShares Biotechnology ETF (IBB) fell 1%.

In corporate news, Accolade (ACCD) shares plunged 44% after Morgan Stanley halved the company's price target to $6 from $12 while keeping its equal-weight rating following its Q1 results and guidance. Truist also cut its price objective to $9 from $14.

FSD Pharma's (HUGE) former board chairman and chief executive owes more than $2.2 million, plus interest, to the company, after a federal court confirmed a November 2022 arbitration award. FSD Pharma shares were falling 4.5%.

Alumis (ALMS) shares fell 20% in their trading debut on Nasdaq Friday after the clinical-stage biopharmaceutical company priced its initial public offering of about 13.1 million shares at $16 per share.

CG Oncology's (CGON) cretostimogene immunotherapy to treat bladder cancer is expected to achieve over $4 billion in non-risk adjusted sales by 2037, BofA Securities said in a note. BofA started coverage of the company with a buy rating and a price objective of $65. CG Oncology shares popped 4.5%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment